CD38 Antibody High Affinity Binding Tumor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CD38 antibodies have limited recognition activity, cytotoxic activity, and tumor inhibition capabilities, necessitating the development of a new antibody with enhanced affinity and specificity for effectively targeting CD38+ tumor cells.
Innovation Solution
A CD38 antibody with a KD value of 1×10-9M or below, capable of binding to CD38 protein with high specificity, inducing ADCC, CDC, and apoptosis, and inhibiting tumor growth, while avoiding binding to unrelated antigens, is developed. This antibody is designed to target CD38+ tumor cells, including multiple myeloma, lymphoma, and leukemia cells, and is formulated as a monoclonal, chimeric, humanized, or fully human antibody.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently developed CD38 antibodies are used, then they can bind to CD38 protein and exhibit some cytotoxic activity, but they have limited recognition activity, limited cytotoxic activity, and limited ability in inhibiting tumors
Solution Approach 1:
The patent improves antibody performance by changing key parameters including binding affinity (achieving KD value of 1×10-9M or below), cytotoxic activity through ADCC and CDC mechanisms, and tumor inhibition capability. These parameter changes transform the limited-performance conventional antibodies into high-performance therapeutic antibodies with enhanced recognition and productivity.
2Measurement precision
If a new CD38 antibody with enhanced affinity is developed, then binding affinity and specificity improve, but development complexity and time increase
Solution Approach 1:
The patent achieves high binding affinity (KD ≤ 1×10-9M) by optimizing antibody parameters through systematic development approaches. The technical solution involves changing affinity parameters, specificity parameters, and functional activity parameters to achieve the desired performance while managing development complexity through structured methodology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively kills and inhibits CD38+ tumor cells, demonstrating enhanced binding affinity and cytotoxic activity compared to existing antibodies, with specific recognition of CD38 protein on tumor cell surfaces and significant ADCC activity, leading to tumor growth inhibition and improved survival rates in preclinical models.
Implementation Method 1
it may bind to the CD38 protein with a higher affinity and specificity; it may inhibit the binding of a CD38 protein to CD38 ligand
Implementation Method 2
it may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC)
Implementation Method 3
it may kill CD38+ cells by means of complement-dependent cytotoxicity (CDC)
Implementation Method 4
it may kill CD38+ cells by means of apoptosis
Data Source
AI summary
Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10−9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.